Company Profiles

driven by the PitchBook Platform

Tarsa Therapeutics

Tarsa Therapeutics
2009 FOUNDED
PRIVATE STATUS
11-50 EMPLOYEES
Later Stage VC LATEST DEAL TYPE (In Progress)
$5.44M LATEST DEAL AMOUNT
$92M TOTAL AMOUNT RAISED
Description

Developer of therapies for the treatment and prevention of postmenopausal osteoporosis and related bone diseases. The company offers an oral formulation of calcitonin for the treatment of postmenopausal osteoporosis in women greater than five years post menopause when alternative treatments are not suitable.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
8 Penn Center, 1628 John F. Kennedy Boulevard
Suite 1400
Philadelphia, PA 19103
United States
+1 (267) 273-7940
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tarsa Therapeutics’s full profile, request a free trial.

Tarsa Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 05-Feb-2016 $5.44M $92M In Progress Generating Revenue
4. Debt - General 13-Aug-2014 000.00 Completed Startup
3. Early Stage VC (Series A) 29-May-2014 000 000.00 00000 Completed Startup
2. Early Stage VC (Series B) 16-Mar-2012 $28M $79.6M $121M Completed Startup
1. Early Stage VC (Series A) 21-Apr-2011 $51.5M $51.5M $71.7M Completed Startup
To view this company’s complete deal history including valuation and funding request access »

Tarsa Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 00,000,000 00.000000 00.0 00.0 00.0 00 00.0 00.000
Series A 00,000,000 00.000000 00.0 00 00 00 00 00.000
To view this company’s complete Cap Table request access »

Tarsa Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Foresite Capital Management Growth/Expansion Minority 000 0000 000000 0
MVM Life Science Partners Venture Capital Minority 000 0000 000000 0
Marker Venture Capital Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
Quaker Partners Management Venture Capital Minority 000 0000 000000 0

Tarsa Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
David Brand Chief Executive Officer, President, Board Member & Co-Founder
James Gilligan Ph.D Chief Scientific Officer & Co-Founder
Ani Railkar Director, CMC
George Maurer Vice President, CMC & Supply
Nicholas LaBella Jr. Vice President, Global Regulatory Affairs
You’re viewing 5 of 7 executives. Get the full list »

Tarsa Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
Daniel Soland Self Board Member 000 0000
David Brand Tarsa Therapeutics Chief Executive Officer, President, Board Member & Co-Founder 000 0000
Eric Bednarski Ph.D MVM Life Science Partners Chairman 000 0000
James Tananbaum MD Foresite Capital Management Board Member 000 0000
Martin Edwards MD Novo Holdings Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 9 board members. Get the full list »